MGC Pharmaceuticals recently unveiled Murcury Pharma, a new medicinal cannabis-based line for Australian and New Zealand markets. MGC has now seen an 85% increase in orders for its product, including Mercury Pharma 100, a prescription-only 100mg/mL canibodol solution and other white label cannabidiol products that are used for treatments such as anxiety, cancer and arthritis. The company’s revenues have now reached over $430,000.